Gottlieb Features Compounding in Farewell Congressional Testimony

Outgoing FDA Commissioner Scott Gottlieb highlighted plans for drug compounding enforcement among the agency’s drug priorities in his final testimony before House appropriators on April 3.
Source: Drug GMP Report